Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply

N Engl J Med. 2024 Jan 18;390(3):287-288. doi: 10.1056/NEJMc2313778.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / surgery

Substances

  • durvalumab
  • Antibodies, Monoclonal